ClinicalTrials.gg
Active, not recruitingNCT05958368AVOCADO-T2DUpdated Sep 25, 2026

Assessing the Value of Avocados on Glycemic Control in Type 2 Diabetes

An interventional study of Avocado and Other Fruit(s) in Diabetes Mellitus, Type 2, Insulin and Fructosamine, sponsored by Pennington Biomedical Research Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Pennington Biomedical Research Center · Not applicable, Interventional, and Treatment

How we know

Updated Sep 25, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Diabetes Mellitus, Type 2 by Pennington Biomedical Research Center — 1 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Pennington Biomedical Research Center.

Enrollment
8th of 15
48 · median 48
Started
2023
with 2 others
No phase
12 of 17
1 open now
Registered
15th of 17
by date

Among the 17 studies in Diabetes Mellitus, Type 2 by Pennington Biomedical Research Center, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2023, is one of 12 with no phase, and was the 15th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 17 studies in Diabetes Mellitus, Type 2 by Pennington Biomedical Research Center is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Diabetes Mellitus, Type 2 by Pennington Biomedical Research Center, or all of them as a file.
02

Study summary

The objective of this study is to assess the effects of Hass Avocados on glycemic control. The investigators hypothesize that Hass Avocado consumption will reduce fasting blood sugar compared to an isocaloric amount of other fruit during controlled feeding.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Insulin
  • Fructosamine
  • C-Reactive Protein
  • Glucose
  • Overweight and Obesity
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant reported diagnosis of Type 2 diabetes
  • between 5.7%-11% (inclusive) and / or fasting blood glucose of ≥ 100 mg/dL
  • 27-50 kg/m2 (inclusive)
  • Age range - 18 - 65 years (inclusive)
  • On stable regimen of all medications (including diabetes) for at least 3 months (brief regimens of medications such as antibiotics, , etc. are permitted)
  • Willing to follow all requirements of study protocol including blood draws
  • Under the care of a physician who will be responsible for managing the subject's diabetes
  • Willing to give release to provide their treating MD with information about the trial

Exclusion criteria

Exclusion Criteria:

  • Not willing or unable to consume study foods including avocados
  • Participation in a weight control program within the past 3 months or weight loss of ≥ 5 kg in the previous 3 months
  • Taking prescription or OTC weight loss medications within last 4 weeks
  • History of a surgical procedure for weight loss in last 5 years (e.g. gastroplasty, gastric by-pass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve)
  • History of major surgery within three months of enrollment
  • Type 1 diabetes, insulin dependent type 2 diabetes, thiazolidinediones (including rosiglitazone and pioglitazone)
  • Renal insufficiency consisting of potassium over 5.5 (mmol/L) on a non-hemolyzed specimen, or a creatinine over 2.5 mg/dL
  • over 3 (mg/dL) or an albumin less than 3 (g/dL)
  • > 3 (IU/L) times the (normal range is 7-56)
  • Evidence of more than 1 severe hypoglycemic event (episode requiring emergency medical services) in the past 12 months, unless the participant's treating physician provides written clearance for participation.
  • Those on higher doses of diuretics (furosemide 40mg or higher or comparable)
  • Unstable heart disease (an ongoing workup or treatment for a cardiac symptom such as unstable angina, coronary ischemia)
  • Presence of implanted cardiac defibrillator
  • Blood pressure ≥180/100 mm Hg. If a potential participant has a BP above the inclusion criteria it is acceptable to re-test this potential participant within one week of the original test.
  • Thyroid disease for which the participant is untreated or has had treatment changed within the last 6 months. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable
  • Uncontrolled gastrointestinal disorders including chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, chronic diarrhea, or active gallbladder disease
  • Current cancer or cancer treatment, or a history of cancer or cancer treatment within the last 3 years. Persons with successfully resected non-melanoma carcinoma of the skin may be enrolled.
  • Dementia, psychiatric illness, or substance abuse that may interfere with adherence (e.g., illness that is currently unstable or resistant to therapy; substance abuse in the past year)
  • Women who are pregnant, lactating, trying to become pregnant or unwilling to use an effective means of
  • Currently consuming >14 alcoholic drinks (1 drink = 12 fl oz beer, 4 fl oz wine or 1.5 fl oz liquor) per week and unwilling to stop intake during study participation
  • Participation in another clinical trial within 30 days prior to enrollment
  • Any other condition or factor which in the opinion of the study physician or investigator makes it inadvisable for the candidate to participate in the trial
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Avocado

    Participants will consume 1 Hass avocado a day.

    Other: Avocado

  • Active comparator
    Other Fruit(s)

    Participants in the other fruit arm will receive other fruits.

    Other: Other Fruit(s)

Interventions

  • OtherAvocado

    The Hass Avocado group will consume 7 avocados a week (1 / day; \~240 kcals/d).

    Also known as: Hass Avocado

  • OtherOther Fruit(s)

    The other fruits group will consume fruit(s) matched to the avocado in energy and form (i.e., solid fruit).

    Also known as: Raisins, Cantaloupe(s), Figs, Pineapple(s), Grapes, Bananas

06

What researchers measure

Primary outcomes

  1. Fasting Blood Glucose

    the primary outcomes are based on within subject concentration change scores

    Time frame: Week 5 - Week 0

Secondary outcomes

  1. Fasting Insulin

    within subject concentration change scores

    Time frame: Week 5 - Week 0

  2. Fructosamine

    within subject concentration change scores

    Time frame: Week 5 - Week 0

  3. Glycated Albumin

    within subject concentration change scores

    Time frame: Week 5 - Week 0

Other outcomes

  1. Blood Glucose

    Continuous Glucose Monitoring

    Time frame: Week 5 - Week 0

  2. Glucose

    Oral Glucose Tolerance Test (OGTT)

    Time frame: Week 5 - Week 0

  3. Insulin

    Oral Glucose Tolerance Test (OGTT)

    Time frame: Week 5 - Week 0

07

Study locations

1 site
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
08

References and documents

Individual participant data

Plan to share: Undecided — Data may be requested. The PI and sponsor will be notified. The proposed research question must be included. All IPD that underlie results in a publication after a DTA with the institution.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Nov 2026, 37 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 37 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Primary completion moved once since we started tracking on Sep 25, 2026: May 2026 → Nov 2026, on Sep 25, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2023
First posted
Jul 24, 2023
StartActual
Oct 10, 2023
Primary completionEst.
Nov 30, 2026was May 2026
CompletionEst.
Dec 15, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 25, 2026
Primary completion
May 30, 2026→Nov 30, 2026
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Recruiting→Active, not recruiting
    Primary completion May 30, 2026→Nov 30, 2026
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05958368
Collaborators
Prachi Singh, Frank L. Greenway, Robbie A. Beyl
Responsible party
John Apolzan (Associate Professor-Research, Pennington Biomedical Research Center) — Principal investigator
First posted
Jul 24, 2023
Start date
Oct 10, 2023
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Sep 25, 2026

Study contacts

John W Apolzan, PhD
principal investigator · Pennington Biomedical Research Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion